June 15, 2025
5 min watch
CHICAGO — On this video, Erica L. Mayer, MD, MPH, discusses the SERENA-6 research, which assessed the efficacy of switching to camizestrant plus a CDK 4/6 inhibitor vs. persevering with customary therapy amongst sufferers with superior breast most cancers.
The outcomes have been offered at ASCO Annual Assembly.
SERENA-6 is a worldwide, double-blind, registrational section 3 trial evaluating the camizestrant (AstraZeneca) mixture in sufferers with hormone receptor-positive, HER2-negative superior breast most cancers with an emergent ESR1 mutation.
Mayer, director of breast most cancers medical analysis at Dana-Farber Most cancers Institute, famous that outcomes confirmed a median PFS of 9 months for sufferers who continued customary therapy with an aromatase inhibitor plus a CDK 4/6 inhibitor vs. 16 months for individuals who switched to the camizestrant mixture.
“Basically, this was a really thrilling presentation, not solely displaying us the good thing about utilizing camizestrant, a well-tolerated oral SERD within the setting of the event of molecular development, but in addition simply introducing us to the idea of serial CDK testing and the concept that one can determine molecular adjustments earlier than there are medical adjustments and that this can be a useful time to intervene,” Mayer mentioned.
Sources/Disclosures
Collapse
Turner NC, et al. Summary LBA4. Offered at: ASCO Annual Assembly; Could 30-June 3, 2025; Chicago.
Disclosures:
AstraZeneca funded this research. Mayer reviews consulting for AstraZeneca, Eli Lilly & Co. and Novartis.
